TheStreet upgraded shares of Kamada (NASDAQ:KMDA) from a c rating to a b rating in a research report released on Friday morning.

Several other analysts have also recently issued reports on the company. Jefferies Group reaffirmed a buy rating and set a $7.00 price objective on shares of Kamada in a report on Thursday, October 12th. Zacks Investment Research raised Kamada from a sell rating to a hold rating in a report on Wednesday, October 25th. ValuEngine raised Kamada from a sell rating to a hold rating in a report on Friday, January 5th. Chardan Capital initiated coverage on Kamada in a report on Friday, February 2nd. They set a buy rating and a $7.00 price objective on the stock. Finally, HC Wainwright reaffirmed a buy rating on shares of Kamada in a report on Thursday, February 8th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $7.00.

Shares of Kamada (NASDAQ KMDA) opened at $5.00 on Friday. The stock has a market capitalization of $201.31, a P/E ratio of 29.41 and a beta of 1.14. Kamada has a twelve month low of $3.75 and a twelve month high of $8.61. The company has a current ratio of 3.30, a quick ratio of 2.58 and a debt-to-equity ratio of 0.02.

Kamada (NASDAQ:KMDA) last issued its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.10. The business had revenue of $35.71 million for the quarter, compared to analysts’ expectations of $32.90 million. Kamada had a return on equity of 9.06% and a net margin of 6.71%. equities research analysts predict that Kamada will post 0.21 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KMDA. Paulson & CO. Inc. increased its position in shares of Kamada by 8.2% during the 2nd quarter. Paulson & CO. Inc. now owns 790,800 shares of the biotechnology company’s stock valued at $4,745,000 after purchasing an additional 60,000 shares during the last quarter. ARK Investment Management LLC bought a new position in shares of Kamada during the 4th quarter valued at approximately $251,000. Worth Venture Partners LLC bought a new position in shares of Kamada during the 3rd quarter valued at approximately $246,000. Navellier & Associates Inc bought a new position in shares of Kamada during the 2nd quarter valued at approximately $303,000. Finally, Analyst IMS Investment Management Services Ltd. increased its position in shares of Kamada by 125.5% during the 3rd quarter. Analyst IMS Investment Management Services Ltd. now owns 89,843 shares of the biotechnology company’s stock valued at $431,000 after purchasing an additional 50,000 shares during the last quarter. 6.26% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.watchlistnews.com/kamada-kmda-rating-increased-to-b-at-thestreet/1863288.html.

Kamada Company Profile

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.